Zobrazeno 91 - 100
of 208
pro vyhledávání: '"Andrew Haydon"'
Publikováno v:
Pigment Cell & Melanoma Research. 30:13-27
Metastasis represents the end product of an elaborate biological process, which is determined by a complex interplay between metastatic tumour cells, host factors and homoeostatic mechanisms. Cutaneous melanoma can metastasize haematogenously or lymp
Autor:
Michael Millward, Alexander M. Menzies, Andrew Haydon, Victoria Atkinson, Benjamin Brady, Jonathan Cebon, Grant A. McArthur, Georgina V. Long, Rachel Roberts-Thomson, Richard F. Kefford, Matteo S. Carlino
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 12:5-12
BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response ra
Autor:
Mark Shilkrut, Ruth Plummer, V. Chiarion-Sileni, Caroline Robert, Eduard Gasal, James Larkin, Axel Hauschild, Richard F. Kefford, Marta Nyakas, Victoria Atkinson, Kohinoor Dasgupta, Dirk Schadendorf, Caroline Dutriaux, Jacob Schachter, Reinhard Dummer, John M. Kirkwood, Mario Mandalà, Tomas Haas, Thierry Lesimple, Laurent Mortier, Georgina V. Long, Andrew Haydon, Mario Santinami
Korrespondenz zu 10.1200/JCO.18.01768 (Hess) und 10.1200/JCO.18.02075 (Hindié)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b203b7a4f3c667c0210306219da5362
https://www.zora.uzh.ch/id/eprint/172226/
https://www.zora.uzh.ch/id/eprint/172226/
Autor:
Jeanette Raleigh, Richard Marais, Jason Li, Jason Callahan, Athena Hatzimihalis, Nathalie Dhomen, Rodney J. Hicks, D. Oudit, Mark A. Dawson, Stephen Q. Wong, Sarah Ftouni, Mark Shackleton, David E. Gyorki, Grant A. McArthur, Victoria Mar, Shahneen Sandhu, Sarah-Jane Dawson, Andrew Haydon, Andrew L. Wallace, Lavinia Tan, Philippa Middlehurst, Rebecca Lee, Michael A. Henderson, Paul Lorigan
Publikováno v:
Tan, L, Sandhu, S, Lee, R J, Li, J, Callahan, J, Ftouni, S, Dhomen, N, Middlehurst, P, Wallace, A, Raleigh, J, Hatzimihalis, A, Henderson, M A, Shackleton, M, Haydon, A, Mar, V, Gyorki, D E, Oudit, D, Dawson, M A, Hicks, R J, Lorigan, P, McArthur, G A, Marais, R, Wong, S Q & Dawson, S-J 2019, ' Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA ', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol. 30, no. 5, 10.1093/annonc/mdz048, pp. 804-814 . https://doi.org/10.1093/annonc/mdz048
Ann Oncol
Ann Oncol
BACKGROUND: The advent of effective adjuvant therapies for patients with resected melanoma has highlighted the need to stratify patients based on risk of relapse given the cost and toxicities associated with treatment. Here we assessed circulating tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c727c6d38bc1097e4d4e2d43d471daf4
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdz048/5369802
https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdz048/5369802
Autor:
Jacob Schachter, Dirk Schadendorf, Eduard Gasal, Laurent Mortier, Marta Nyakas, Egbert de Jong, Caroline Dutriaux, Reinhard Dummer, Mario Santinami, Georgina V. Long, John M. Kirkwood, Mario Mandalà, Victoria Atkinson, Vanna Chiarion-Sileni, Andrew Haydon, Caroline Robert, Christine-Elke Ortmann, James Larkin, Richard F. Kefford, Axel Hauschild
9582 Background: In the COMBI-AD trial (NCT01682083), 12 mo of adjuvant D+T led to significant improvement of RFS vs PBO (hazard ratio [HR], 0.47; P < .001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42511b4b46cd8c4fde9d100d74a0872
Autor:
John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
Publikováno v:
Journal of Clinical Oncology
J Clin Oncol
J Clin Oncol
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT0168208
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8
https://doi.org/10.5167/uzh-158265
https://doi.org/10.5167/uzh-158265
Autor:
Dirk, Schadendorf, Axel, Hauschild, Mario, Santinami, Victoria, Atkinson, Mario, Mandalà, Vanna, Chiarion-Sileni, James, Larkin, Marta, Nyakas, Caroline, Dutriaux, Andrew, Haydon, Caroline, Robert, Laurent, Mortier, Thierry, Lesimple, Ruth, Plummer, Jacob, Schachter, Kohinoor, Dasgupta, Stephanie, Manson, Roy, Koruth, Bijoyesh, Mookerjee, Richard, Kefford, Reinhard, Dummer, John M, Kirkwood, Georgina V, Long
Publikováno v:
The Lancet. Oncology. 20(5)
In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAFCOMBI-AD was a randomised, double-blind, placebo-controlled, phase 3 study done at 169 sites in 25 countries. Study participants were aged 18 years or older and had co
Autor:
John M. Kirkwood, Monique Tan, Caroline Dutriaux, James E. Larkin, Dirk Schadendorf, Vanna Chiarion Sileni, Reinhard Dummer, Laurent Mortier, Georgina V. Long, Andrew Haydon, Mario Santinami, Mike Lau, Jacob Schachter, Caroline Robert, Axel Hauschild, Victoria Atkinson, Tomas Haas, Hiya Banerjee, Mario Mandalà, Marta Nyakas
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s2
not available.
Autor:
Chrystelle Brignone, Prashanth Prithviraj, Christian Mueller, Melissa Eastgate, Frederic Triebel, Amitesh Roy, Andrew Haydon, Adnan Khattak, Victoria Atkinson
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundTo evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.Methods
Autor:
V. Atkinson, Andrew Haydon, P.A. Ascierto, C. Robert, Christian U. Blank, A.C.J. van Akkooi, Matteo S. Carlino, A. M. M. Eggermont, Clemens Krepler, Stefan Suciu, Adnan Khattak, Andrey Meshcheryakov, Mario Mandalà, Michal Kicinski, Georgina V. Long, Sandrine Marreaud, Nageatte Ibrahim, S. Dalle, S. Puig Sarda, Shahneen Sandhu
Publikováno v:
Annals of Oncology. 31:S1175